Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Biotix’s Tip Eject is a pipette tip reloading system that allows users to reload to Biotix racks without transfer devices. The packaging is translucent, which allows for easy tip identification while fully protecting tips from contamination due to contact and environmental particulates. Tip Eject cards are made from 100 percent recycled polypropylene, which helps labs reduce waste without sacrificing the quality of pipette tips.
Thermo Fisher Scientific’s Dionex UltiMate 3000 biocompatible rapid separation liquid chromatography system is designed to combine ultrahigh-performance liquid chromatography with the corrosion-resistant flow path required to analyze proteins, peptides, nucleic acids, and biotherapeutics.
NorDx, a member of MaineHealth, is the nation’s first clinical laboratory to acquire Sysmex America’s XN series automated hematology analyzers. The Sysmex XN-3000 configuration enables enhanced diagnostic capabilities and greater efficiency, which transforms NorDx into an accountable care laboratory model and shepherds in a new era of performance standards for quality care in New England, according to Stan Schofield, president of NorDx and senior VP of MaineHealth.
Tanner Scientific’s TN1500 tissue-embedding center is a user-friendly workstation that was designed with the input of hundreds of histology lab supervisors. The workstation features a four-line digital display for easy programming (all surface temperatures can be viewed and adjusted without the need to scroll), a fully adjustable cryoplate that can be placed on the right or left side, an adjustable-intensity bright LED light on a flexible tube, a 2.6-gallon tank capacity, an extra-large magnifying glass on a flexible tube, and more.
Medical’s highly specific p40 mouse monoclonal anti-p40 [BC28] demonstrated similar sensitivity and specificity to the company’s rabbit polyclonal p40, staining 97 percent (65/67) of cases of lung squamous cell carcinoma and zero percent (0/71) cases of lung adenocarcinoma, in an in-house study. In addition, the antibody has significantly less background and does not stain macrophages.
MolecularMD Corp. has entered into a license agreement to obtain rights to commercialize patent-pending intellectual property pertaining to use of LKB1 for diagnostic, prognostic, and predictive uses in humans in non-small cell lung cancer.
The African Society of Laboratory Medicine, working in conjunction with the CDC, Clinton Health Access Initiative, UNAIDS, and WHO/AFRO, has partnered with SoftTech Health in a program to network the laboratories continentwide with the LabQMS (Quality Management Software).
Eppendorf North America and the journal Science are now accepting applications for the 2013 Eppendorf and Science Prize for Neurobiology—an annual international research prize of $25,000. The prize is awarded to one young scientist for his or her outstanding contributions to neurobiology research. Researchers 35 years old or younger are invited to apply by June 15.
Roche and Hamilton Robotics have introduced an integrated platform that enables automated DNA sample enrichment for Roche’s 454 GS Junior sequencer. The platform builds on the integration of Roche’s REM e system with Hamilton’s Microlab Nimbus NGS workstation, resulting in reduced hands-on time, minimized operational variability, and more consistent results.
Evogen has entered into a nonexclusive license agreement with Focus Diagnostics granting worldwide rights to incorporate Evogen HyBeacons PCR probe technology into Focus Diagnostics’ molecular diagnostic products and services.
